Healthcare Stocks

Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

 Sareum (SAR) returns 700% in a year: Is this small-cap share still a good buy?

HIGHLIGHTS Saerum raised £2.37 million in June 2021 through two subscription contracts with high-net-worth individuals. In July 2021, the company received approval from the US Patent and Trademark Office for the use of SDC-1802 drug molec...

Read More...
Faron (LON: FARN) & Novacyt (LON: NCYT) shares. Should you buy them now?

Faron (LON: FARN) & Novacyt (LON: NCYT) shares. Should you buy them now?

Highlights  Faron Pharmaceuticals Oy share prices suffered a sharp correction of around 7 per cent. For the H1 2021 ended 30 June 2021, Novacyt recorded revenues of £94.7 million, up by over 50% compared to £63.3 million in H1 ...

Read More...
Inspira supports Vectura’s (LON: VEC) £1.1bn acquisition by Philip Morris

Inspira supports Vectura’s (LON: VEC) £1.1bn acquisition by Philip Morris

Highlights  Inspira Pharmaceuticals comes out to support Vecutra’s £1.1 billion takeover by US-based Philip Morris International amid rising criticism due to potential threats to the UN’s sustainability goals and future co...

Read More...
UK’s Psychedelic sector and potential investment opportunities

UK’s Psychedelic sector and potential investment opportunities

Highlights Decades of research has shown Psychedelic substance such as LSD and Psilocybin can treat the mental disorder more efficiently than conventional therapies. The market size of the Psychedelic treatment was at USD five billion in 2020 a...

Read More...
Is it the right time to invest in these 5 FTSE listed cannabis stocks?

Is it the right time to invest in these 5 FTSE listed cannabis stocks?

Very recently, in 2018 the UK legalised the medicinal use of cannabis. Medical cannabis, which is used to treat the pain and specific illnesses was first legalised in the United states for the treatment of Alzheimer's disease and other medical cond...

Read More...
Pfizer booster shot - Which other vaccines may require booster doses?

Pfizer booster shot - Which other vaccines may require booster doses?

Summary  According to BioNTech, a booster shot of the two-shot Pfizer vaccine is expected to serve as a better strategy to fight new variant than altering the existing vaccine product. AstraZeneca is yet not sure if a booster dose of the C...

Read More...
Pfizer and Flynn in the dock for overcharging NHS for anti-epilepsy drugs

Pfizer and Flynn in the dock for overcharging NHS for anti-epilepsy drugs

Summary  The Competition and Markets Authority has accused pharma major Pfizer and Flynn of overcharging for the anti-epileptic drug. Both Pfizer and Flynn exploited a loophole so that they would not face price regulation. The UK's Co...

Read More...
Why have Pfizer and Moderna raised prices for vaccines in the EU?

Why have Pfizer and Moderna raised prices for vaccines in the EU?

Summary US-based COVID-19 vaccine manufacturers Pfizer and Moderna increased prices of their vaccines in the latest European Union supply contracts. The terms of the deal for 2.1 billion vaccine doses until 2023 were renegotiated, as the phase ...

Read More...
5 top FTSE healthcare stocks below £1

5 top FTSE healthcare stocks below £1

Summary  Investors often chose to invest in low-priced stocks in the healthcare sector, as few of such firms will emerge as big gainers in the long term. Events such as successful research attempts or a new drug launch are expected to boos...

Read More...
AstraZeneca’s (LON: AZN) shares and the latest buzz around

AstraZeneca’s (LON: AZN) shares and the latest buzz around

AstraZeneca (LON: AZN), the pharmaceutical major,  which has been news for last some time due to its Covid-19 vaccine, is once again creating buzz after receiving approval in China for its small cell lung cancer drug Imfinzi.  Shares of t...

Read More...
Lens on 5 AIM listed pharma stocks as CMA slaps £260-million fine on drug makers

Lens on 5 AIM listed pharma stocks as CMA slaps £260-million fine on drug makers

Summary  CMA slapped fines of over £260 million on drug makers after investigations revealed NHS was overcharged close to a decade for hydrocortisone tablets. Prices of hydrocortisone increased by over 10,000 per cent over the years....

Read More...